Comparison of carcinoembryonic antigen prognostic value in serum and tumour tissue of patients with colorectal cancer by Li, M et al.
Original article doi:10.1111/j.1463-1318.2008.01591.x
Comparison of carcinoembryonic antigen prognostic value in
serum and tumour tissue of patients with colorectal cancer
M. Li*, J.-Y. Li†, A.-L. Zhao†, J.-S. He†, L.-X. Zhou†, Y.-A. Li† and J. Gu*
*Gastrointestinal Surgery Unit and †Department of Pathology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, China
Received 9 February 2008; accepted 11 April 2008
Abstract
Objective Carcinoembryonic antigen (CEA) in the
serum and the tumour tissue of colorectal cancer
(CRC) patients is the most commonly used tumour
marker for the diagnosis and evaluation of prognosis or
recurrence after treatment, but the role remains contro-
versial. The objective of this study was to compare the
prognostic value of CEA both in serum and tumour
tissue in CRC.
Method A total of 173 patients with CRC in stages I–III
were retrospectively assessed with the endpoint of recur-
rence or metastasis after curative operation. CEA was
assessed both in serum and tumour tissue.
Results 37.0% (64 ⁄ 173) patients had a high level of
CEA in serum (S-CEA) while 39.3% (68 ⁄ 173) had high
CEA in tumour tissue (T-CEA). There were no signif-
icant differences in clinico-pathological features between
the low and high S-CEA or T-CEA groups. The high S-
CEA group had a worse prognosis than the low S-CEA
group but the difference was not signiﬁcant. The high T-
CEA group had a signiﬁcantly poorer prognosis than the
low T-CEA group (P = 0.028) in the univariate analysis.
The multivariate analysis demonstrated that the T-CEA
was an independent prognosis factor in CRC. Because
many factors would affect the concentration of S-CEA,
there was no correlation between S-CEA and T-CEA
directly.
Conclusion Our study suggests that a high T-CEA
concentration may be a useful and independent predictor
for poor outcome after surgery in CRC patients. It may
be stronger than a high preoperative serum CEA level.
Keywords Colorectal cancer, prognosis, carcinoembry-
onic antigen
Introduction
Colorectal cancer (CRC) is one of the most common
tumour types in the world, with about 400 000 deaths
annually [1,2]. In the United States, despite a slight
decrease in its incidence and mortality during the past
two decades, CRC remains the third most common
cancer, affecting about 140 000 people and accounting
for 50 000 cancer-related deaths per year [3]. In China,
where the incidence rate was initially low, due to the
changes in lifestyle and nutritional habits, the CRC rate is
increasing by 4.2% annually [4,5].
Carcinoembryonic antigen (CEA) is the most
commonly used tumour marker for the diagnosis of
CRC and evaluation of prognosis or recurrence after
treatment. The guideline of National Comprehensive
Cancer Network (NCCN) indicated that for T2 or
greater lesions, a CEA test is recommended at baseline
and every 3 months for 2 years [6]. CEA can be detected
and quantitatively measured in the serum and the tumour
tissue of CRC patients, but their role in the prognosis of
CRC remains controversial. The objective of this study
was to compare the prognostic value of CEA both in
tumour tissue and in serum of the patients with CRC.
Method
Patients
This retrospective study included 173 patients from the
database of Beijing Cancer Hospital between January
1995 and November 1999 who satisﬁed the following
criteria: (1) sporadic CRC diagnosed in our hospital; (2)
no preoperative therapy; (3) curative resection with free
margin; (4) no synchronic liver or other organ metastasis
detected; (5) followed up until patients had metastasis or
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closure of the study (1 August 2003); (6) staged
according to the TNM system recommended by the
American Joint Committee on Cancer (AJCC) [7].
The criterions for exclusion were: (1) severe dysfunc-
tion of heart, brain, lung, kidney and liver; (2) death
attributable to causes other than CRC; (3) accompanying
urological or genital tumour; (4) accompanying cancers
other than CRC.
Detection of the CEA in serum
Five millilitres of venous blood was obtained from each
patient 1 week before operation. CEA in serum (S-CEA)
measurements were done by the department of clinical
laboratoryinourhospitalusingelectrochemiluminescence
immunoassay with Elecsys system 2010 (Roche Holding
Ltd, Basel, Switzerland). The cut-off value of S-CEA
recommended by the manufacturers for diagnosis was
5n g⁄ ml. We classiﬁed the 173 patients into high S-CEA
group (> 5 ng ⁄ ml) and low S-CEA group (£ 5n g⁄ ml).
Immunohistochemistry
The CEA in the tumour tissue which we named T-CEA
was determined by the method of immunohistochemistry.
In each patient, formalin-ﬁxed and parafﬁn-embedded
tumour blocks were cut into 5 lm thick sections (average
area 2.0 cm
2), deparafﬁnized in xylene, and rehydrated.
Antigen retrieval was performed in 0.1 M citric acid buffer
(pH 6.0) in a 650 W microwave for 15 min. Endogenous
peroxidase activity was blocked with 0.3% hydrogen
peroxide in 100% methanol for 30 min. Immunohisto-
chemistry was performed as Power Vision
TM two-step
histostaining (Immuno Vision Technologies Co., Daly
City, CA, USA). Primary CEA antibody (Zymed Labora-
tories Inc., South San Francisco, CA, USA) was diluted as
1:50 and sections were incubated overnight at 4 C. After
three washes in PBS (5 min), sections were incubated for
30 min in anti-mouse secondary antibody from a
PicTure
TM-PV6000 Kit (Zymed Laboratories Inc.). Anti-
bodybindingwasvisualizedusinga3,3-diaminobenzidine
(DAB)kit(VectorLabs,Burlingame,CA,USA)according
to the manufacturer’s instructions.
Scoring
For general negative controls, the primary antibodies were
replaced by phosphate buffer solution (PBS). All slides
were scored by two independent and well-trained pathol-
ogists, without the knowledge of clinical and pathologic
parameters or the patients’ outcomes. And in cases of
scoring disagreement, a third independent assessment was
performed. For all slides, at least 10 high power ﬁelds at
400· magniﬁcation were chosen randomly and > 1000
carcinoma cells were counted for each section.
Stained slides were examined to identify the cellular
localization of CEA immunoreactivity for both intensity
(), +, ++, and +++) and proportion (0%, 1–5%, 6–25%,
26–50%, 51–75% and > 75%) of tumour cells stained.
Integer values were assigned to the scores of intensity (0–
3) and proportion of tumour cells stained (0–5). These
values were multiplied together to provide a single score
for each case [8]. For T-CEA, the low and high
expression scores were deﬁned as < 6 and ‡ 6, respec-
tively (Fig. 1) [9].
Statistical analysis
All statistical calculations were performed using SPSS
version 10.0 (SPSS Inc., Chicago, Illinois, USA). The
differences in the clinico-pathological characteristics
between low and high S-CEA or T-CEA expression were
performed by Pearson chi-square. The relationship
between S-CEA and T-CEA was also calculated by
Pearson chi-square. Disease-free survival time (in
months) was measured from the date of surgery to the
time of event (recurrence or metastasis) or to the last
census prior to closure of the study (1 August 2003).
Kaplan–Meier survival analysis with the Log Rank test was
used to evaluate the prognosis of serum and tissue CEA
in CRC. Multivariate analysis was performed with Cox’s
proportional hazard regression model to assess the effects
of different variables on patients’ survival. Differences
were taken as signiﬁcant when P (two-tailed) was < 0.05.
Results
In this study, there were 173 patients with CRC including
86 male subjects and 87 female subjects. The median age
Figure 1 High expression of CEA in colorectal cancer (‡ 75%).
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(64 ⁄ 173) patients had a high level of S-CEA including 29
male subjects and 35 female subjects, while 63.0%
(109 ⁄ 173) patients were in the low S-CEA group.
39.3% (68 ⁄ 173) patients were in the high T-CEA group
(38 male subjects and 30 female subjects).
Comparison of clinico-pathological features between
high and low S-CEA or T-CEA
There were no signiﬁcant differences in gender, age,
tumour size, tumour gross type, mucin production,
differentiation grade, venous invasion, stage distribution,
T and N classiﬁcation between the low and high S-CEA
or T-CEA groups (Table 1).
The relationship between S-CEA and T-CEA groups
There was no signiﬁcant relationship between groups of
S-CEA and T-CEA (P = 0.215) (Table 2).
Relationship of S-CEA to disease-free survival by
univariate analyses
The mean disease-free survival time after operation in the
low S-CEA group was longer than patients of high level
of S-CEA (68.4 vs 51.3 months, 95% CI), but there was
no signiﬁcant difference between them (P = 0.3709)
(Fig. 2).
Relationship of T-CEA with disease-free survival by
univariate analyses
Kaplan–Meier survival analysis with the Log Rank test
showed that the mean disease-free survival time after
operation in the low T-CEA group was signiﬁcantly
longer than in the high T-CEA group (72.0 vs
55.8 months, P = 0.028) (Fig. 3).
Multivariate analysis of prognostic factors in colorectal
cancer
In order to evaluate which clinico-pathological features
were independent predictors of CRC outcomes, we
analysed our ﬁndings with a Cox proportional hazards
model while gender, age, tumour size, histological type,
differentiation grade, venous invasion, stage, S-CEA and
T-CEA expressions served as covariates. Finally, four
independent factors including histological type, stage,
venous invasion and T-CEA were found to be signiﬁcant
prognostic factors for the disease-free survival of CRC. S-
CEA was not found to be a signiﬁcant prognostic
predictor (Table 3).
Discussion
Carcinoembryonic antigen was ﬁrst described in 1965 by
Gold and Freedman [10,11], when they identiﬁed an
antigen that was present in both fetal colon and colon
adenocarcinoma but that was absent from the healthy
adult colon, hence its name, carcinoembryonic antigen.
Subsequent work showed that CEA was also present in
certain healthy tissues, although concentrations in
tumours were on average 60-fold higher than in the
nonmalignant tissues [12]. Now CEA gene is classiﬁed as
a member of the immunoglobulin supergene family
[13,14].
Carcinoembryonic antigen is the most widely used
tumour marker worldwide and certainly the most fre-
quently used marker in CRC. It could be detected and
measured both in serum and in CRC tissue [15]. The
prognostic role of increased CEA level in serum and
tumour tissue of CRC patients remains unknown.
In the current study of 173 CRC patients, there was
no signiﬁcant difference in the disease-free survival time
between low and high S-CEA. The S-CEA is not an
independent prognostic factor for CRC by multivariate
analysis. Previous experiments have reported that an
elevated preoperative serum CEA level is a predictor for
poor survival after CRC resection [16,17], some even
suggesting that serum CEA was an independent factor of
CRC prognosis [18,19]. By contrast, some studies
demonstrated that serum CEA had signiﬁcant prognostic
value only in some special stages or the signiﬁcance is not
independent of staging system, which is similar to our
results [20–22]. The present study, along with some
previous reports, had revealed no signiﬁcant relationship
between preoperative serum CEA and tumour tissue
CEA concentrations [23–27]. The reasons for these
inconsistent results may be due to CEA production,
release and metabolism. As we know, many factors may
affect this course. Firstly, well-differentiated CRCs pro-
duce more CEA than poorly differentiated specimens.
Similarly, S-CEA tends to be higher in patients with well-
differentiated tumours compared with those poorly
differentiated tumours [28,29]. Thus, a lack of differen-
tiation or poor differentiation may explain why some
patients with advanced CRC do not have increased S-
CEA values [30]. Secondly, the liver is the primary site for
the metabolism of CEA. Consequently, S-CEA can be
increased from patients with impaired liver function such
as certain nonmalignant liver diseases [31,32]. Thirdly,
some reports suggest that patients with tumours in the
left side of the colon generally have a higher incidence of
increased S-CEA than those with malignancies on the
right side of the colon [33,34]. Fourthly, Sugarbaker
[35] showed that bowel obstruction may give rise to
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can reduce serum CEA values. Fifthly, S-CEA values can
be almost doubled by smoking [36]. Finally, patients
with aneuploid CRC have been shown to produce higher
S-CEA than those with tumours with a near diploid
pattern [37]. All these ﬁndings make the S-CEA and
T-CEA unparallel.
The results of this series suggest that the prognostic
value of T-CEA concentration may be superior to that of
preoperative S-CEA level. The disease-free survival time
after surgery for patients with a high T-CEA concentra-
tion was signiﬁcantly shorter in univariate analysis than
those with a low T-CEA. Multivariate analysis also
revealed that T-CEA status (high or low) was an
independent prognostic factor in CRC. The hazard of
Table 1 Clinico-pathological characteristics in S-CEA and T-CEA group n (%).
Total
(n = 173)
Low S-CEA
(n = 109)
High S-CEA
(n = 64) P-value
Low T-CEA
(n = 105)
High T-CEA
(n = 68) P-value
Gender
Male 86 (49.7) 57 (52.3) 29 (45.3) 0.375 48 (45.7) 38 (55.9) 0.191
Female 87 (50.3) 52 (47.7) 35 (54.7) 57 (54.3) 30 (44.1)
Age
Median 59.0 56.4 58.1 0.408 61 56.50 0.603
Range 27–85 33–85 27–82 27–85 30–76
Tumour size
£ 5 cm 78 (45.1) 48 (44.0) 30 (46.9) 0.844 45 (42.9) 33 (48.5) 0.657
> 5 cm 91 (52.6) 58 (53.2) 33 (51.6) 58 (55.2) 33 (48.5)
Unknown 4 (2.3) 3 (2.8) 1 (1.6) 2 (1.9) 2 (3.0)
Gross type
Ulcerative 131 (75.7) 82 (75.2) 49 (76.6) 0.843 77 (73.3) 54 (79.4) 0.362
Polypoid 42 (24.3) 27 (24.8) 15 (23.4) 28 (26.7) 14 (20.6)
Mucin production
Mucinous adenocarcinoma 13 (7.5) 6 (5.5) 7 (10.9) 0.191 9 (8.6) 4 (5.9) 0.512
Adenocarcinoma 160 (92.5) 103 (94.5) 57 (89.1) 96 (91.4) 64 (94.1)
Differentiation grade
Undifferentiated 7 (4.1) 5 (4.6) 2 (3.1) 0.871 6 (5.7) 1 (1.5) 0.318
Poorly 31 (17.9) 21 (19.3) 10 (15.6) 21 (20) 10 (14.7)
Moderate 90 (52.0) 56 (51.4) 34 (53.1) 50 (47.6) 40 (58.8)
Well 45 (26.0) 27 (24.8) 18 (28.1) 28 (26.7) 17 (25)
Venous invasion
No 140 (77.8) 89 (81.7) 51 (79.7) 0.751 86 (80.4) 54 (75.8) 0.684
Yes 33 (22.2) 20 (18.3) 13 (20.3) 19 (19.6) 14 (24.2)
Stage
I 22 (11.3) 17 (15.6) 5 (7.8) 0.179 16 (5.8) 6 (15.6) 0.130
II 75 (40) 49 (45.0) 26 (40.6) 49 (47.1) 26 (34.4)
III 76 (48.7) 43 (39.4) 33 (51.6) 40 (47.1) 36 (50)
T
T1 2 (1.1) 2 (1.8) 0 (0) 0.517 2 (1.9) 0 (0) 0.392
T2 27 (15.6) 19 (17.4) 8 (12.5) 18 (17.1) 9 (13.2)
T3 106 (61.3) 66 (60.6) 40 (62.5) 60 (57.2) 46 (67.7)
T4 38 (22) 22 (20.1) 16 (25) 25 (23.8) 13 (19.1)
N
N0 97 (56.1) 66 (60.6) 31 (48.4) 0.099 65 (61.9) 32 (47.1) 0.099
N1 40 (23.1) 24 (22.0) 16 (25) 20 (19.1) 20 (29.4)
N2 30 (17.3) 17 (15.6) 13 (20.3) 15 (14.2) 15 (22.0)
N3 6 (3.5) 2 (1.8) 4 (6.3) 5 (4.8) 1 (1.5)
Table 2 The relationship between S-CEA and T-CEA groups.
Low T-CEA
(n = 105)
High T-CEA
(n = 68) P-value
Low S-CEA
(n = 109)
70 39 0.215
High S-CEA
(n = 64)
35 29
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CEA group is 1.587 times compared with the low T-CEA
group. It is coincident with the study of Nakagoe
et al.[38]. We think that the prognostic value of
T-CEA concentration may be more reliable than pre-
operative S-CEA levels. However, strict statistical pro-
cess in a large number of patients is needed to clarify the
issue.
In conclusion, our study suggests that a high T-CEA
concentration may be a useful and independent predictor
for poor outcome after surgery in CRC patients, and it
may be stronger than a high preoperative serum CEA
level.
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